Hosted on MSN1y
FDA probing serious risk of T-cell malignancies in CAR-T cell therapy patients (update)
The regulator said it had determined that the risk of T-cell malignancies applied to all currently approved BCMA-directed and CD19-directed genetically modified autologous CAR-T cell immunotherapies.
pharmaphorum2d
Roche buys off-the-shelf CAR-T player Poseida for $1bn
The Swiss pharma group has agreed a $9 per share deal to acquire Poseida, valuing the company at around $1 billion, with another $500 million potentially payable to shareholders in a contingent value ...
Yahoo Finance21d
Aditum Bio and Leads Biolabs Announce the Formation of Oblenio Bio to Develop a Tri-Specific T-Cell Engager for Autoimmune Disorders
Leads Biolabs grants Oblenio Bio an exclusive option to license LBL-051, a first-in-class CD19xBCMAxCD3 tri-specific T-cell engager antibody OAKLAND, Calif. and NANJING, China, Nov. 7, 2024 ...
Nature12mon
Enabling T cell therapy for established solid tumors using genetic-enhancing modifiers
More importantly, most patients treated with CD19 or B cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells will eventually relapse despite having initial complete responses.
Yahoo Finance21d
Aditum Bio and Leads Biolabs Announce the Formation of Oblenio Bio to Develop a Tri-Specific T-Cell Engager for Autoimmune Disorders
Recent clinical data from CD19 and BCMA targeted therapies have demonstrated compelling efficacy in difficult-to-treat autoimmune diseases. Despite these promising results, there is a continued ...
manilatimes21d
Aditum Bio and Leads Biolabs Announce the Formation of Oblenio Bio to Develop a Tri-Specific T-Cell Engager for Autoimmune Disorders
Leads Biolabs grants Oblenio Bio an exclusive option to license LBL-051, a first-in-class CD19xBCMAxCD3 tri-specific T-cell engager antibody Recent clinical data from CD19 and BCMA targeted therapies ...